EGFR Mutation Clinical Trials

10 recruitingLast updated: June 17, 2026

There are 10 actively recruiting egfr mutation clinical trials across 28 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Shanghai, Shanghai Municipality, China, Hefei, Anhui, China, Chengdu, Sichuan, China. Updated daily from ClinicalTrials.gov.


EGFR Mutation Trials at a Glance

10 actively recruiting trials for egfr mutation are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Shanghai, Hefei, and Chengdu. Lead sponsors running egfr mutation studies include AstraZeneca, Bayer, and Abbisko Therapeutics Co, Ltd.

Browse egfr mutation trials by phase

Treatments under study

About EGFR Mutation Clinical Trials

Looking for clinical trials for EGFR Mutation? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new EGFR Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about EGFR Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 1

Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

EGFR Mutation-positive NSCLC
AstraZeneca12 enrolled3 locationsNCT07500987
Recruiting
Phase 3

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation
Instituto Nacional de Cancerologia de Mexico28 enrolled1 locationNCT05852990
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Phase 2

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Fudan University53 enrolled1 locationNCT06775743
Recruiting
Phase 1

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc.18 enrolled3 locationsNCT07315113
Recruiting
Phase 1Phase 2

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 2

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd54 enrolled5 locationsNCT06668103
Recruiting
Phase 2

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Non-small Cell Lung Cancer (NSCLC)Leptomeningeal MetastasesBrain Metastases+2 more
Li-kun Chen70 enrolled1 locationNCT06728865
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation
Suzhou Genhouse Bio Co., Ltd.94 enrolled6 locationsNCT06306456